Psychotic symptoms in Parkinson's disease: pathophysiology and management
- PMID: 15155149
- DOI: 10.1517/eods.3.3.209.31071
Psychotic symptoms in Parkinson's disease: pathophysiology and management
Abstract
Parkinson's disease (PD) is a chronic neurodegenerative disease, in which mainly dopaminergic neurons in the substantia nigra in the brain degenerate, leading to a depletion of dopamine (DA) in the striatum. The most important motor disturbances of the disease are bradykinesia (slowing down of movement), hypokinesia (poverty of movement), rigidity (muscle stiffness), tremor and postural instability. Besides these well-known motor symptoms, non-motor symptoms may develop, such as depression, cognitive impairment and psychosis. Psychotic symptoms constitute a relatively common but nevertheless serious complication, with visual hallucinations and paranoid delusions often being most prominent. These symptoms are important contributors to patient and caregiver distress and are often important risk factors for nursing home placement. Exogenous (related to therapeutic interventions) factors are of major importance but endogenous (related to the disease process itself) factors might also contribute to the development of psychotic symptoms in PD. Therapeutic strategies comprise reduction of antiparkinsonian treatment, cholinesterase inhibitors and atypical antipsychotics. As psychotic symptoms in PD are often influenced by both endogenous and exogenous factors, a combination of strategies may be chosen.
Similar articles
-
Management of psychosis in Parkinson's disease.Int J Clin Pract. 2003 May;57(4):295-300. Int J Clin Pract. 2003. PMID: 12800461 Review.
-
PD-related psychosis: pathophysiology with therapeutical strategies.J Neural Transm Suppl. 2006;(71):31-7. doi: 10.1007/978-3-211-33328-0_4. J Neural Transm Suppl. 2006. PMID: 17447413 Review.
-
Psychosis in nursing home patients with Parkinson's disease.J Am Med Dir Assoc. 2004 May-Jun;5(3):167-73. doi: 10.1097/01.JAM.0000123028.10575.45. J Am Med Dir Assoc. 2004. PMID: 15115577 Review.
-
Treatment of behavioural symptoms and dementia in Parkinson's disease.Fundam Clin Pharmacol. 2005 Apr;19(2):133-46. doi: 10.1111/j.1472-8206.2005.00317.x. Fundam Clin Pharmacol. 2005. PMID: 15810893 Review.
-
Psychosis in Parkinson's disease.J Geriatr Psychiatry Neurol. 2004 Sep;17(3):127-36. doi: 10.1177/0891988704267457. J Geriatr Psychiatry Neurol. 2004. PMID: 15312276 Review.
Cited by
-
Cerebrospinal fluid biomarkers for dementia with lewy bodies.Int J Alzheimers Dis. 2010 Oct 17;2010:536538. doi: 10.4061/2010/536538. Int J Alzheimers Dis. 2010. PMID: 21048932 Free PMC article.
-
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.J Mol Neurosci. 2012 Jan;46(1):145-52. doi: 10.1007/s12031-011-9539-x. Epub 2011 May 12. J Mol Neurosci. 2012. PMID: 21562737
-
G-protein coupled receptors and synaptic plasticity in sleep deprivation.World J Psychiatry. 2021 Nov 19;11(11):954-980. doi: 10.5498/wjp.v11.i11.954. eCollection 2021 Nov 19. World J Psychiatry. 2021. PMID: 34888167 Free PMC article. Review.
-
Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan.BMJ Open. 2018 Aug 29;8(8):e023302. doi: 10.1136/bmjopen-2018-023302. BMJ Open. 2018. PMID: 30158237 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials